Prolidase deficiency is an autosomal recessive disorder characterized by mental retardation and various skin lesions. Cultured skin fibroblasts were obtained from two independent patients with abnormal prolidase. Using the polymerase chain reaction, we amplified the entire coding region of human prolidase mRNA derived from patients' fibroblasts. Nucleotide sequence analysis of amplified cDNA products revealed a G to A substitution at position 826 in exon 12, where aspartic acid was replaced by asparagine at the amino acid residue 276, in cells from both patients. An analysis of the DNA showed that the substitution was homozygous.
Introduction
Prolidase is a homodimeric enzyme catalyzing the hydrolysis of dipeptides with carboxy-terminal proline. This enzyme and enlarged CRM.
We identified a cDNA clone corresponding to the human prolidase (5) , and determined the nucleotide sequence and the primary structure of the enzyme (6) . The prolidase gene is located on chromosome 19 (6) and consists of 15 exons and 14 introns, the span being > 130 kb (2a). We have now examined the molecular events in two patients with polypeptide positive prolidase deficiency. The nucleotide sequences of cDNAs from the patients were analyzed by making comparisons with the sequence of cDNA and genomic DNA from a normal individual. We obtained evidence for the same amino acid substitution in the mutant enzymes, thereby confirming that this substitution is responsible for defects in the activity.
Methods
Materials. Purified human prolidase, a monoclonal antibody (EP2) directed to human prolidase, and antiserum raised against human prolidase were prepared as described (2) . [a-32P]dCTP (3, 000 Ci/ mmol) was purchased from ICN Radiochemicals (Irvine, CA). Nitrocellulose membrane was obtained from Schleicher and Schuell (Dassel, FRG) . Restriction enzymes, T4 DNA ligase, and Taq DNA polymerase were purchased from Takara Shuzo Co. (Kyoto, Japan) and were used essentially as recommended by the supplier. Avian myeloblastosis virus reverse transcriptase and the reagent lipofectin were purchased from Bethesda Research Laboratories (Gaithersburg, MD). A 7-deaza sequencing kit was obtained from Toyobo Co. (Osaka, Japan). Oligonucleotide primers were synthesized using a DNA synthesizer (model 381 A; Applied Biosystems Inc., Foster City, CA).
Polymerase chain reaction of mRNA. Total cellular RNAs from controls' and patients' fibroblasts were prepared using the guanidium thiocyanate procedure (7) . Five oligonucleotide primers were synthesized for polymerase chain reaction (PCR) of mRNA, an oligonucleotide primer C, and two sets ofoligonucleotide primers (A1, A2, B1, B2) consisting of 20 bases complementary to the published normal sequence of human prolidase (6) (Fig. 1 1, 678) are complementary to the sequence of prolidase (6) . Of these, A2, B2, and C represent reverse or antisense sequences. Two segments, 933-and 975-bp long, were amplified with primer sets of A and B, respectively. The base number for the A of the ATG start codon and the terminal G of the UAG stop codon are indicated.
A specific first-strand cDNA copy of human prolidase RNA was made from 10 tg of total cellular RNA using the oligonucleotide primer C complementary to the RNA strand that serves as a primer for reverse transcriptase (8) . Amplification ofthe first strand ofcDNA was carried out according to the method of Saiki et al. (9) (11) . Approximately 1 sg of DNA was amplified with the use of a set of oligonucleotide primers (Fig. 3) complementary to the normal sequence of the human prolidase gene. The 5' primer (24 mer) corresponded to the sequence in intron 11 and the 3' primer (25 mer) to the sequence in intron 12 (2a). PCR was performed as described above, except for 2 min at 720C for the extension. The amplified DNA fragment was digested with a restriction enzyme of a Taq I and analyzed on a 2% agarose gel.
Plasmid construction. A wild type ofcDNA clone (pPD-l) covering the entire coding region of human prolidase was constructed by PCR of the mRNA from normal human fibroblasts. A wild type of expression clone (pEPD-W) was constructed as follows: the 1.7-kb Eco RI fragment derived from pPD-l was isolated and inserted into an expression vector pCAGGS, a derivative of pAGS-3 (12) , which has the cytomegalovirus intermediate early enhancer, the chicken fl-actin promoter, and a polyadenylation signal of the rabbit fl-globin gene. A mutant type of expression clone (pEPD-M) was produced by substituting the 154-bp Sac I fragment (784-937) ofhuman prolidase cDNA insert in pEPD-W with the 154-bp Sac I fragment (784-937) with a point mutation. The Sac I fragment was derived from a subclone ofthe patient's cDNA, which included the sequence ofthe putative mutation (position 826). The nucleotide sequence and a proper 5' to 3' orientation ofthe prolidase cDNA in each clone was confirmed by restriction digestion, gel analysis, and sequence. The plasmids grown in Escherichia coli HBlBO were purified by two cycles of cesium chlorideethidium bromide centrifugation.
Cells andDNA transfection. Cultured NIH 3T3 cells and fibroblasts with prolidase deficiency were used for transfection. Transfection of DNA was performed using lipofection (13), according to instructions given by the supplier. Nearly confluent cells (80%) in 75-cm dishes were washed twice with 6 ml ofRPMI 1640 medium (Gibco Laboratories, Grand Island, NY), and 9 ml of RPMI 1640 medium containing 10 jg of DNA and 30 ,ig of lipofection was added. To normalize for any variability in the transfection efficiency, plasmid pCHl 10 which contained the E. coli lac Z gene sequence under the control of Simian virus 40 enhancer-promoter (14), was cotransfected as an internal standard. The transfected cells were incubated for 6 h in a 7% CO2 atmosphere at 370C, after which 9 ml of RPMI 1640 medium with 20% FCS (Gibco Laboratories) was added. After incubation of this preparation for 12 h, the medium was replaced with 18 ml of fresh medium with 10% FCS and the cells were harvested 2 d later.
Cell extracts were prepared as described (3) and used for protein assay, immune precipitation, and immune blot analyses. Part of the cell extracts were assayed for fl-galactosidase activity by incubation with O-nitrophenyl-B-D-galactopyranoside as described (15) . The amount of protein was measured by a dye-binding method (kit from Bio-Rad Laboratories, Richmond, CA).
Enzyme assay, immune precipitation, and immune blot. Prolidase activities in the crude cell extracts were measured as described (16) . Immune precipitation ofhuman prolidase with the mouse monoclonal antibody (EP2) was carried out as described (2) . The prolidase activity in the immune complex was measured as described (3) and conditions for immune blots were also as described (2, 3) .
Results
Human prolidase is composed of 492 amino acid residues synthesized from the 1,482-base coding region of the mRNA sequence (6) . Although the PCR technique has been used to isolate DNA fragments as large as 2,000 bp, the efficiency of the technique is improved when target sequences of < 1,000 bp are used (17) . As shown in Fig. 1 , we used primer sets of A and B to amplify 933-and 975-bp segments, respectively. Together, these overlapping segments covered the entire coding region of human prolidase mRNA.
Two fibroblast strains from two independent patients with polypeptide positive prolidase deficiency were analyzed. Patient 1 (female) (18) died at age 36, and patient 2 (male) (19) was 8 yr old. Both patients presented with skin lesions. These two families are apparently unrelated; however, both families came from the Middle East. Using primer sets, specific prolidase cDNA fragments were successfully amplified from total cellular RNA from the control or the patients. Each amplified DNA was the same size, as compared with findings in the control, thereby suggesting that there were no deletions or insertions in mRNA in the patients' fibroblasts.
Sequencing of the amplified cDNA from these patients revealed a single-base substitution (G to A at position 826) that resulted in the replacement of Asp with Asn at amino acid residue 276 in exon 12 (Figs. 2 and 3 ). This replacement was detected in all five independent subclones after amplification from the fibroblasts of patient 1 and four subclones from patient 2 with the primer set of A and B. To confirm that the substitution was not due to PCR or to a cloning artifact, and was homozygous, we analyzed genomic DNA from the patients' fibroblasts. The nucleotide sequence, including exon 12, was amplified with the primer set as shown in Fig. 3 . Using this primer set, a 222-bp fragment was amplified in the case ofthe control (Fig. 3, lane N) , patient 1 (lane P6), and patient 2 (lane P7). When amplified DNA from the control was digested with Taq I, 171-and 5 1-bp fragments were generated (lane N). On the other hand, the 222-bp fragments from patients 1 and 2 (Fig. 3, lanes P6 and P7) remained unchanged after digestion with Taq I. The G to A substitution at position 826 in exon 12 resulted in the elimination of a Taq I site, which cleaves at the 5'-TCGA-3' but not the 5'-TCAA-3' sequence. This result suggests that these patients have a homozygous allele and that the substitution was not due to a PCR artifact of the mRNA. In other patients with a prolidase deficiency there was a lack of prolidase activity and CRM (3), and the pattern was similar (lanes P1-PS) to the control, hence the probability of a different mutation(s).
An analysis of transfection and expression was made to determine if the substitution was indeed responsible for the prolidase deficiency in these patients. We constructed a pEPD-W with a normal sequence of human prolidase and a pEPD-M with a G to A substitution at position 826. The results are shown in Fig. 4 . Endogenous prolidase in the NIH 3T3 cell was present (data not shown), but only human prolidase immune-precipitated with EP2. An immunological protein of 56 kD crossreactive with the anti-human prolidase antibody is present in cells transfected with pEPD-M or pEPD-W (Fig. 4 A, lanes 3 and 4) but not in those transfected with pCAGGS (lane 2). Prolidase activity was detected in cells transfected with pEPD-W and corresponding to 60% of the normal human fibroblasts (Fig. 4 B) , whereas prolidase activity was either absent or markedly reduced in cells transfected with pCAGGS or pEPD-M. Thus, the cells transfected with pEPD-M could synthesize immunological polypeptide, but the catalytic activity was severely impaired. When pEPD-W transfected into fibroblasts from patients, the prolidase activity corresponding to the activity seen in the normal human fibroblasts was recovered (Fig. 5) .
The nucleotide substitution led to replacement ofAsp with Asn, in association with a change in the secondary structure of the prolidase protein subunit (from a-helix to ,-sheet). Further analysis of the expression confirmed that this replacement was responsible for the defective enzyme activity, with no relation to polymorphism.
The plasmid pEPD-W constructed from the expression vector pCAGGS and cDNA insert of human prolidase could synthesize a polypeptide with prolidase activity in the transfected cells. This result clearly revealed the expression of the human prolidase with enzymatic activity in the NIH 3T3 cells, therefore demonstrating that the human prolidase cDNA we used (pPD-l) contained all of the sequence information required for expression of the intact prolidase gene product. The 56-kD product achieved a proper structure and conformation of a homodimer and generated activity of the enzyme. On the other hand, the plasmid pEPD-M with the Asp to Asn substitution synthesized a polypeptide with a markedly decreased enzyme activity. These results were compatible with our data on fibroblasts (3) and confirmed that the homozygous substitution was responsible for the markedly decreased enzyme activity.
These two patients are products of nonconsanguineous matings and these two families had no apparent kinship. However, these families were from the Middle East area and the particular mutation demonstrated in this study seemed to have originated in this area.
Restoration of prolidase activity after transfection implies that the mutation does not affect the processing of wild-type prolidase. Transformed cell lines expressing human prolidase after gene transfer represent a new source of enzyme for biochemical characterization. Similarly, transformed cells containing mutant prolidase genes, cloned from affected individuals with prolidase deficiency, can be used to obtain the mutant prolidase enzyme.
As active prolidase can be expressed in mammalian cells using a proper clone, the possibility of replacement gene therapy for prolidase deficiency can be given serious consideration.
Discussion
Mutations can lead to decreased functions of prolidase, resulting in the clinical and biochemical phenotype of a prolidase deficiency. We obtained evidence that the G to A substitution in a region of the prolidase gene, which was homozygous in these cells, resulted in a marked decrease in prolidase activity, hence a phenotype of polypeptide positive prolidase deficiency. immune precipitated activities were calculated based on the amount of protein in the cell extracts and expressed by the percentages in the control fibroblasts.
